Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIVACTIL vs ANAFRANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
Major depressive disorder
Obsessive-compulsive disorder (OCD),Off-label: depression, panic disorder, chronic pain, cataplexy associated with narcolepsy, premature ejaculation
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Terminal elimination half-life of clomipramine is approximately 21-26 hours; its active metabolite, desmethylclomipramine, has a half-life of approximately 36-42 hours. Steady-state is achieved within 7-14 days.
Primarily hepatic via CYP2D6 and other microsomal enzymes; active metabolite desmethylprotriptyline.
Primarily hepatic via CYP1A2, CYP3A4, CYP2C19, and CYP2D6; active metabolite desmethylclomipramine formed via N-demethylation.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Renal (primarily as conjugated metabolites, ~60-70% over 72 hours); fecal (biliary excretion of ~10-20%); <2% excreted unchanged in urine.
Approximately 90% bound, primarily to albumin and α1-acid glycoprotein.
97.6% bound primarily to alpha1-acid glycoprotein and albumin.
Vd approximately 8–15 L/kg, indicating extensive tissue distribution with higher CNS concentration than plasma.
Approximately 12-17 L/kg, indicating extensive tissue distribution.
Oral bioavailability approximately 30–40% due to first-pass metabolism (extensive hepatic cytochrome P450 biotransformation).
Oral bioavailability is approximately 45-55% due to first-pass metabolism. IV administration yields 100%.
For GFR <10 m L/min: use with caution and consider 50% dose reduction; no specific guidelines for GFR 10-50 m L/min.
No specific guidelines. Use with caution in severe renal impairment (Cr Cl <30 m L/min); consider dose reduction based on tolerability.
Child-Pugh class B or C: reduce dose by 50-75%; avoid use in severe hepatic impairment.
Child-Pugh A: no adjustment needed. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Not recommended for children <12 years; for adolescents 12-18 years: 5-10 mg orally twice daily, max 60 mg/day.
Not recommended for children <10 years. For adolescents: initial 25 mg PO daily, increase slowly to 3 mg/kg/day or 100 mg/day maximum (whichever is lower).
Initiate at 5 mg orally twice daily; increase slowly with monitoring for orthostatic hypotension and anticholinergic effects.
Initial: 10 mg PO daily; increase slowly to 30-50 mg/day. Monitor for orthostatic hypotension, sedation, and anticholinergic effects.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality and Antidepressant Drugs: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
Activation of mania/hypomania,Seizure threshold lowering,Cardiovascular toxicity (QT prolongation, arrhythmias),Angle-closure glaucoma,Urinary retention,Hepatic impairment,Concomitant MAOI use
May increase risk of suicidal thoughts/behaviors; serotonin syndrome when used with other serotonergic drugs; lowering of seizure threshold; orthostatic hypotension; anticholinergic effects (e.g., urinary retention, blurred vision); cardiac conduction abnormalities; QT prolongation; neuroleptic malignant syndrome; angle-closure glaucoma; hyperpyrexia; withdrawal symptoms upon abrupt discontinuation; use with caution in patients with cardiovascular disease, hepatic impairment, renal impairment, history of seizures, and elderly patients.
Hypersensitivity to protriptyline,Recent myocardial infarction,Concurrent MAOI therapy,QT prolongation or concomitant QT-prolonging drugs
Hypersensitivity to clomipramine or other tricyclics; concurrent use or within 14 days of MAO inhibitors; recent myocardial infarction; history of seizure disorder; narrow-angle glaucoma; urinary retention; concurrent use with linezolid or methylene blue.
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce) if taking with MAOIs; however, protriptyline alone has no significant tyramine interaction. Grapefruit juice may increase protriptyline levels; avoid high intake. Alcohol can potentiate CNS depression. High-fiber foods may slightly reduce absorption; take at same time each day.
Avoid grapefruit and grapefruit juice as they may increase clomipramine levels. Take with food to reduce gastric upset. Avoid excessive caffeine; it may increase side effects like anxiety or tremors. Limit alcohol due to additive CNS depression.
First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withdrawal, respiratory distress, tachycardia, and hyperirritability if used near term.
First trimester: Limited data; possible increased risk of congenital heart defects (RR ~1.3). Second/third trimester: Risk of neonatal withdrawal syndrome (jitteriness, feeding difficulties, respiratory distress) and persistent pulmonary hypertension of the newborn (PPHN) with late exposure.
Present in breast milk; M/P ratio 0.5–1.9. Cases of drowsiness and poor feeding in infants reported; avoid breastfeeding or use with caution.
Anafranil (clomipramine) is excreted into breast milk. M/P ratio approximately 0.5-1.0. Relative infant dose estimated 1-2% of maternal weight-adjusted dose. Monitor infant for drowsiness, feeding difficulties, and weight loss. Generally compatible with caution.
Decreased plasma concentrations due to increased volume of distribution; consider dose adjustment based on clinical response and serum levels; start at low dose and titrate.
Due to increased plasma volume and enhanced hepatic metabolism in pregnancy, serum levels may decrease by up to 50%. Consider dose adjustment based on clinical response and trough levels; typical increase by 25-50% may be needed in later pregnancy. Postpartum, reduce dose to prepregnancy levels over 1-2 weeks.
VIVACTIL (protriptyline) is a tricyclic antidepressant with a more activating profile; it has the fastest onset of weight gain among TCAs. It is often used for ADHD, narcolepsy, and depression with psychomotor retardation. Due to its long half-life (54-92 hours), dosing should be conservative in elderly. It has a high anticholinergic burden, risking urinary retention and cognitive impairment in older adults. Avoid in patients with recent MI or arrhythmias. Monitor EKG and drug levels in suspected overdose.
Anafranil (clomipramine) is a tricyclic antidepressant (TCA) primarily used for obsessive-compulsive disorder (OCD). Monitor for QT prolongation, especially in patients with cardiac risk factors or on other QT-prolonging drugs. Due to anticholinergic effects, use cautiously in elderly, those with BPH, or narrow-angle glaucoma. Start low and titrate slowly to minimize side effects. Therapeutic response may take 2-4 weeks. Do not discontinue abruptly due to withdrawal symptoms.
Take exactly as prescribed; do not stop suddenly as withdrawal may occur.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts or worsening depression immediately.,May cause dry mouth, constipation, blurred vision; use sugarless candy or gum for dry mouth.,Rise slowly from sitting or lying to prevent dizziness.,Do not take with MAOIs or within 14 days of stopping them.,Notify doctor if you experience fast/irregular heartbeat, difficulty urinating, or seizures.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,It may take several weeks to feel the full benefit; do not stop suddenly.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts, worsening depression, or mood changes immediately.,May cause drowsiness, dizziness, or blurred vision; avoid driving until you know how it affects you.,Dry mouth, constipation, and urinary retention are common; increase fluid intake and dietary fiber.,Use sun protection; this medication can increase sensitivity to sunlight.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VIVACTIL vs ANAFRANIL, answered by our medical review team.
VIVACTIL is a Tricyclic Antidepressant that works by Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.. ANAFRANIL is a Tricyclic Antidepressant that works by Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VIVACTIL and ANAFRANIL depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VIVACTIL is: 10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.. The standard adult dose of ANAFRANIL is: Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VIVACTIL and ANAFRANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VIVACTIL is classified as Category C. First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withd. ANAFRANIL is classified as Category C. First trimester: Limited data; possible increased risk of congenital heart defects (RR ~1.3). Second/third trimester: Risk of neonatal withdrawal syndrome (jitteriness, feeding dif. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.